Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Neurocrine Biosciences (NBIX) has a market cap of $14.86 billion USD. According to our data, Neurocrine Biosciences is ranked No.1205 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $14.86 B |
7.55%
|
| Dec 31, 2024 | $13.82 B |
3.60%
|
| Dec 29, 2023 | $13.34 B |
10.31%
|
| Dec 30, 2022 | $12.09 B |
40.24%
|
| Dec 31, 2021 | $8.62 B |
-11.14%
|
| Dec 31, 2020 | $9.70 B |
-10.83%
|
| Dec 31, 2019 | $10.88 B |
50.53%
|
| Dec 31, 2018 | $7.23 B |
-7.96%
|
| Dec 29, 2017 | $7.86 B |
100.49%
|
| Dec 30, 2016 | $3.92 B |
-31.59%
|
| Dec 31, 2015 | $5.73 B |
153.22%
|
| Dec 31, 2014 | $2.26 B |
139.19%
|
| Dec 31, 2013 | $0.95 B |
24.87%
|
| Dec 31, 2012 | $0.76 B |
-12.00%
|
| Dec 30, 2011 | $0.86 B |
11.26%
|
| Dec 31, 2010 | $0.77 B |
180.88%
|
| Dec 31, 2009 | $0.28 B |
-15.00%
|
| Dec 31, 2008 | $0.32 B |
-29.52%
|
| Dec 31, 2007 | $0.46 B |
-56.43%
|
| Dec 29, 2006 | $1.05 B |
-83.39%
|
| Dec 30, 2005 | $6.35 B |
27.24%
|
| Dec 31, 2004 | $4.99 B |
-9.61%
|
| Dec 31, 2003 | $5.52 B |
19.45%
|
| Dec 31, 2002 | $4.62 B |
-11.01%
|
| Dec 31, 2001 | $5.19 B |
54.90%
|
| Dec 29, 2000 | $3.35 B |
33.84%
|
| Dec 31, 1999 | $2.51 B |
260.00%
|
| Dec 31, 1998 | $0.70 B |
-12.70%
|
| Dec 31, 1997 | $0.80 B |
-21.25%
|
| Dec 31, 1996 | $1.01 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 ACADIA Pharmaceuticals
ACAD
|
$2.97 B |
-3.328 M
|
USA
|
 Supernus Pharmaceuticals
SUPN
|
$2.12 B |
-0.015 B
|
USA
|
 Intra-Cellular Therapies
ITCI
|
$13.51 B |
0.000 M
|
USA
|
 Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
 Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
 Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
 Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
 Jazz Pharmaceuticals
JAZZ
|
$7.35 B |
-0.000 M
|
Ireland
|
 Neurocrine Biosciences
NBIX
|
$14.86 B |
-0.000 M
|
USA
|
 Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
 Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
 AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
 AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
 Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
| Market Cap | = | NBIX Stock Price | * | NBIX Shares Outstanding |
| = | $146.80 | * | 0.10 B | |
| = | $14.86 B |